Contact
The newspaper El Periódico de Catalunya reports on the study by Miquel Coll, group leader of the Structural Biology of Proteins and Nucleic Acids, and Their Complexes Laboratory at IRB Barcelona, who has found a second use for an existing drug. The AIDS drug 'Isentress' could also be used against herpesviruses, which cause various diseases, some of which are very serious. "The inhibitor is not toxic at therapeutic levels for humans because it is already on the market, which should facilitate the testing of toxicity," says Miquel Coll.
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
